Invariant Natural Killer T-cell Control of Type 1 Diabetes: a Dendritic Cell Genetic Decision of a Silver Bullet or Russian Roulette

Overview

Journal Diabetes

Specialty Endocrinology

Date 2009 Nov 12

PMID 19903740

Citations 18

Authors

John P Driver

Felix Scheuplein

Yi-Guang Chen

Alexandra E Grier

S Brian Wilson

David V Serreze

Affiliations

Soon will be listed here.

Abstract

Objective: In part, activation of invariant natural killer T (iNKT)-cells with the superagonist alpha-galactosylceramide (alpha-GalCer) inhibits the development of T-cell-mediated autoimmune type 1 diabetes in NOD mice by inducing the downstream differentiation of antigen-presenting dendritic cells (DCs) to an immunotolerogenic state. However, in other systems iNKT-cell activation has an adjuvant-like effect that enhances rather than suppresses various immunological responses. Thus, we tested whether in some circumstances genetic variation would enable activated iNKT-cells to support rather than inhibit type 1 diabetes development.

Research Design And Methods: We tested whether iNKT-conditioned DCs in NOD mice and a major histocompatibility complex-matched C57BL/6 (B6) background congenic stock differed in capacity to inhibit type 1 diabetes induced by the adoptive transfer of pathogenic AI4 CD8 T-cells.

Results: Unlike those of NOD origin, iNKT-conditioned DCs in the B6 background stock matured to a state that actually supported rather than inhibited AI4 T-cell-induced type 1 diabetes. The induction of a differing activity pattern of T-cell costimulatory molecules varying in capacity to override programmed death-ligand-1 inhibitory effects contributes to the respective ability of iNKT-conditioned DCs in NOD and B6 background mice to inhibit or support type 1 diabetes development. Genetic differences inherent to both iNKT-cells and DCs contribute to their varying interactions in NOD and B6.H2(g7) mice.

Conclusions: This great variability in the interactions between iNKT-cells and DCs in two inbred mouse strains should raise a cautionary note about considering manipulation of this axis as a potential type 1 diabetes prevention therapy in genetically heterogeneous humans.

Citing Articles

-the struggles and battles of innate-like effector T lymphocytes with microbes.

Joyce S, Okoye G, Driver J Front Immunol. 2023; 14:1117825.

PMID: 37168859 PMC: 10165076. DOI: 10.3389/fimmu.2023.1117825.

Unaltered influenza disease outcomes in swine prophylactically treated with α-galactosylceramide.

Gu W, Madrid D, Yang G, Artiaga B, Loeb J, Castleman W Dev Comp Immunol. 2020; 114:103843.

PMID: 32871161 PMC: 8119227. DOI: 10.1016/j.dci.2020.103843.

CD70 Inversely Regulates Regulatory T Cells and Invariant NKT Cells and Modulates Type 1 Diabetes in NOD Mice.

Ye C, Low B, Wiles M, Brusko T, Serreze D, Driver J J Immunol. 2020; 205(7):1763-1777.

PMID: 32868408 PMC: 7787366. DOI: 10.4049/jimmunol.2000148.

Two to Tango: Dialogue between Adaptive and Innate Immunity in Type 1 Diabetes.

Sun L, Xi S, He G, Li Z, Gang X, Sun C J Diabetes Res. 2020; 2020:4106518.

PMID: 32802890 PMC: 7415089. DOI: 10.1155/2020/4106518.

CD38 promotes pristane-induced chronic inflammation and increases susceptibility to experimental lupus by an apoptosis-driven and TRPM2-dependent mechanism.

Garcia-Rodriguez S, Rosal-Vela A, Botta D, Cumba Garcia L, Zumaquero E, Prados-Maniviesa V Sci Rep. 2018; 8(1):3357.

PMID: 29463868 PMC: 5820326. DOI: 10.1038/s41598-018-21337-6.

References

Kojo S, Seino K, Harada M, Watarai H, Wakao H, Uchida T . Induction of regulatory properties in dendritic cells by Valpha14 NKT cells. J Immunol. 2005; 175(6):3648-55. DOI: 10.4049/jimmunol.175.6.3648. View

Pearson T, Markees T, Serreze D, Pierce M, Marron M, Wicker L . Genetic disassociation of autoimmunity and resistance to costimulation blockade-induced transplantation tolerance in nonobese diabetic mice. J Immunol. 2003; 171(1):185-95. DOI: 10.4049/jimmunol.171.1.185. View

Teng M, Westwood J, Darcy P, Sharkey J, Tsuji M, Franck R . Combined natural killer T-cell based immunotherapy eradicates established tumors in mice. Cancer Res. 2007; 67(15):7495-504. DOI: 10.1158/0008-5472.CAN-07-0941. View

Van Kaer L . alpha-Galactosylceramide therapy for autoimmune diseases: prospects and obstacles. Nat Rev Immunol. 2005; 5(1):31-42. DOI: 10.1038/nri1531. View

Vuckovic S, Withers G, Harris M, Khalil D, Gardiner D, Flesch I . Decreased blood dendritic cell counts in type 1 diabetic children. Clin Immunol. 2007; 123(3):281-8. DOI: 10.1016/j.clim.2007.03.002. View

Flores-Romo L, Bjorck P, Duvert V, van Kooten C, Saeland S, Banchereau J . CD40 ligation on human cord blood CD34+ hematopoietic progenitors induces their proliferation and differentiation into functional dendritic cells. J Exp Med. 1997; 185(2):341-9. PMC: 2196112. DOI: 10.1084/jem.185.2.341. View

Shi F, Flodstrom M, Balasa B, Kim S, van Gunst K, Strominger J . Germ line deletion of the CD1 locus exacerbates diabetes in the NOD mouse. Proc Natl Acad Sci U S A. 2001; 98(12):6777-82. PMC: 34429. DOI: 10.1073/pnas.121169698. View

Hammond K, Poulton L, Palmisano L, Silveira P, Godfrey D, Baxter A . alpha/beta-T cell receptor (TCR)+CD4-CD8- (NKT) thymocytes prevent insulin-dependent diabetes mellitus in nonobese diabetic (NOD)/Lt mice by the influence of interleukin (IL)-4 and/or IL-10. J Exp Med. 1998; 187(7):1047-56. PMC: 2212199. DOI: 10.1084/jem.187.7.1047. View

Takahashi K, Honeyman M, Harrison L . Impaired yield, phenotype, and function of monocyte-derived dendritic cells in humans at risk for insulin-dependent diabetes. J Immunol. 1998; 161(5):2629-35. View

10.

Liang S, Latchman Y, Buhlmann J, Tomczak M, Horwitz B, Freeman G . Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses. Eur J Immunol. 2003; 33(10):2706-16. DOI: 10.1002/eji.200324228. View

11.

Chen Y, Driver J, Silveira P, Serreze D . Subcongenic analysis of genetic basis for impaired development of invariant NKT cells in NOD mice. Immunogenetics. 2007; 59(9):705-12. DOI: 10.1007/s00251-007-0236-4. View

12.

Keir M, Liang S, Guleria I, Latchman Y, Qipo A, Albacker L . Tissue expression of PD-L1 mediates peripheral T cell tolerance. J Exp Med. 2006; 203(4):883-95. PMC: 2118286. DOI: 10.1084/jem.20051776. View

13.

Chen Y, Chen J, Osborne M, Chapman H, Besra G, Porcelli S . CD38 is required for the peripheral survival of immunotolerogenic CD4+ invariant NK T cells in nonobese diabetic mice. J Immunol. 2006; 177(5):2939-47. DOI: 10.4049/jimmunol.177.5.2939. View

14.

Taraban V, Rowley T, Al-Shamkhani A . Cutting edge: a critical role for CD70 in CD8 T cell priming by CD40-licensed APCs. J Immunol. 2004; 173(11):6542-6. DOI: 10.4049/jimmunol.173.11.6542. View

15.

Behar S, Porcelli S . CD1-restricted T cells in host defense to infectious diseases. Curr Top Microbiol Immunol. 2007; 314:215-50. DOI: 10.1007/978-3-540-69511-0_9. View

16.

Jansen A, van Hagen M, Drexhage H . Defective maturation and function of antigen-presenting cells in type 1 diabetes. Lancet. 1995; 345(8948):491-2. DOI: 10.1016/s0140-6736(95)90586-3. View

17.

Fujii S, Shimizu K, Hemmi H, Steinman R . Innate Valpha14(+) natural killer T cells mature dendritic cells, leading to strong adaptive immunity. Immunol Rev. 2007; 220:183-98. DOI: 10.1111/j.1600-065X.2007.00561.x. View

18.

Shimizu K, Kurosawa Y, Taniguchi M, Steinman R, Fujii S . Cross-presentation of glycolipid from tumor cells loaded with alpha-galactosylceramide leads to potent and long-lived T cell mediated immunity via dendritic cells. J Exp Med. 2007; 204(11):2641-53. PMC: 2118481. DOI: 10.1084/jem.20070458. View

19.

Fujii S, Shimizu K, Smith C, Bonifaz L, Steinman R . Activation of natural killer T cells by alpha-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein. J Exp Med. 2003; 198(2):267-79. PMC: 2194082. DOI: 10.1084/jem.20030324. View

20.

Hong C, Lee H, Oh M, Kang C, Hong S, Park S . CD4+ T cells in the absence of the CD8+ cytotoxic T cells are critical and sufficient for NKT cell-dependent tumor rejection. J Immunol. 2006; 177(10):6747-57. DOI: 10.4049/jimmunol.177.10.6747. View